KR20190087233A - The purple sweet potato composition manufactured by low temperature extraction method and the use thereof - Google Patents
The purple sweet potato composition manufactured by low temperature extraction method and the use thereof Download PDFInfo
- Publication number
- KR20190087233A KR20190087233A KR1020180005766A KR20180005766A KR20190087233A KR 20190087233 A KR20190087233 A KR 20190087233A KR 1020180005766 A KR1020180005766 A KR 1020180005766A KR 20180005766 A KR20180005766 A KR 20180005766A KR 20190087233 A KR20190087233 A KR 20190087233A
- Authority
- KR
- South Korea
- Prior art keywords
- sweet potato
- purple sweet
- composition
- present
- activity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 244000017020 Ipomoea batatas Species 0.000 title claims description 95
- 235000002678 Ipomoea batatas Nutrition 0.000 title claims description 95
- 238000000605 extraction Methods 0.000 title description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000012141 concentrate Substances 0.000 claims abstract description 22
- 230000002785 anti-thrombosis Effects 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims description 22
- 208000007536 Thrombosis Diseases 0.000 claims description 20
- 230000036541 health Effects 0.000 claims description 19
- 235000013376 functional food Nutrition 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000003064 anti-oxidating effect Effects 0.000 claims description 4
- 238000001816 cooling Methods 0.000 abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 239000000284 extract Substances 0.000 description 20
- 235000008504 concentrate Nutrition 0.000 description 18
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 108090000190 Thrombin Proteins 0.000 description 11
- 229960004072 thrombin Drugs 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000011449 brick Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- 108010094028 Prothrombin Proteins 0.000 description 8
- 102100027378 Prothrombin Human genes 0.000 description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000002949 hemolytic effect Effects 0.000 description 8
- 229940039716 prothrombin Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- -1 ring Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000007711 solidification Methods 0.000 description 6
- 230000008023 solidification Effects 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 229940019700 blood coagulation factors Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000021403 cultural food Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 235000019985 fermented beverage Nutrition 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008138 Cerebral venous thrombosis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 244000289527 Cordyline terminalis Species 0.000 description 1
- 235000009091 Cordyline terminalis Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- ZNEMYFCJOCCUJN-VFFTVRQLSA-N Europine Chemical compound C1C[C@H](O)[C@H]2C(COC(=O)[C@@](O)([C@H](C)OC)C(C)(C)O)=CCN21 ZNEMYFCJOCCUJN-VFFTVRQLSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- XAVJHWWXMYRTDC-UHFFFAOYSA-N europine Natural products COC(C)C(O)(C(=O)OCC1CCN2CCC(O)C12)C(C)(C)O XAVJHWWXMYRTDC-UHFFFAOYSA-N 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000000974 natural food coloring agent Substances 0.000 description 1
- 230000017570 negative regulation of blood coagulation Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000001047 purple dye Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 저온추출 자색고구마(Ipmoea batatas L. Lam) 조성물의 제조 방법, 상기 방법에 의하여 제조되는 저온추출 자색고구마 및 이의 용도에 관한 것으로서, 보다 상세하게는, 수세 정선된 자색고구마를 세절하고, 이를 50~70℃의 열수로 추출한 후, 냉각 및 농축하여 자색고구마 농축액을 조제하고, 상기 자색고구마 농축액에 정제수를 가하여 최종 25~35브릭스로 조절하여 제조되는 자색고구마 조성물의 제조 방법과 상기 제조 방법에 의한 저온추출 자색고구마 조성물 및 상기 자색고구마 조성물을 포함하는 항산화 활성 및 항혈전 활성을 갖는 식품 및 의약 조성물과 건강 기능 식품에 관한 것이다.The present invention relates to a method for producing low-temperature extracted purple sweet potato ( Ipmoea The present invention relates to a method for producing a sweet potato batatas L. Lam composition, a low temperature extracted purple sweet potato produced by the above method, and a use thereof, and more particularly, And then cooling and concentrating the mixture to prepare a purple sweet potato concentrate. The purified purplish sweet potato composition is prepared by adding purified water to the purple sweet potato concentrate and controlling the final purple sweet potato concentration to 25-35 Bricks. The present invention relates to a food and medicinal composition having an antioxidative activity and an antithrombotic activity and a health functional food containing the purple sweet potato composition.
산소 호흡을 하는 생명체는 산화적 스트레스를 피할 수 없으며, 이러한 산화적 스트레스는 발암, 노화, 염증 반응 등의 다양한 질병과 연관되어 있다. 따라서, 이러한 산화적 스트레스를 제거하기 위한 다양한 항산화제가 개발되어 왔으며, 대표적으로 비타민 C와 BHT(butylated hydroxy toluene), tocopherol, cysteine, glutathione 등이 알려져 있다. 그러나, 기존의 화학합성 항산화제의 잠재적 위험성과 항산화제 공급의 경제적 어려움이 증가되면서 소비자들은 값싼 천연재료 유래의 항산화제를 원하게 되었고, 경제성과 안전성이 확보된 새로운 강력한 항산화제의 필요성은 지속적으로 증가되고 있다. Oxygen-breathing organisms can not avoid oxidative stress, and these oxidative stresses are associated with a variety of diseases such as cancer, aging, and inflammation. Therefore, a variety of antioxidants have been developed to eliminate such oxidative stress. Vitamin C and butylated hydroxy toluene (BHT), tocopherol, cysteine, and glutathione are known. However, as the potential risks of existing chemical synthetic antioxidants and the economic difficulties of supplying antioxidants have increased, consumers have been demanding antioxidants derived from cheap natural materials, and the need for new powerful antioxidants, .
또한, 인체 구성 성분으로서의 혈액은 산소, 영양분, 노폐물의 운반 기능과 완충 작용, 체온 유지, 삼투압 조절 및 이온 평형 유지, 수분 일정 유지, 액성 조절 작용, 혈압의 유지 및 조절, 생체 방어 등 다양한 중요 기능들을 가지고 있다. 정상적인 혈액 순환은 체내에서의 혈액 응고 반응계와 혈전 용해 반응계가 상호 보완적으로 조절되면서 혈액 순환을 용이하게 하며, 이들 중 혈액 응고 반응계의 기작은 혈관벽에 혈소판이 점착, 응집하여 혈소판 혈전을 형성한 후, 혈액 응고계가 활성화되어 혈소판 응집괴를 중심으로 피브린 혈전이 형성되는 것으로 보고되어 있다. 한편, 피브린 혈전의 생성은 수많은 혈액 응고 인자들의 여러 단계 반응을 거쳐 피브린 응고에 관여하는 트롬빈이 활성화되어, 최종적으로 피브리노겐으로부터 피브린 단량체를 생성하게 하며, 피브린 단량체들은 칼슘에 의해 중합되어, 혈소판과 내피세포에 결합하게 되며 XIII 인자에 의해 교차 결합된 피브린 폴리머를 형성하면서 영구적인 혈전을 생성하게 된다. 또한, 트롬빈은 혈소판, V 인자, VII 인자들을 활성화시켜 혈액 응고 반응을 촉진시키는 등 혈전 생성에 중추적 역할을 하게 된다. 따라서, 트롬빈의 활성 저해물질은 과다한 혈액 응고 이상으로 발생하는 다양한 혈전성 질환에 매우 유용한 예방 및 치료제로 사용될 수 있다. 한편, 내인성 혈전 생성 경로에는 XII 인자, XI 인자, XII 인자, IX 인자, X 인자의 순차적 활성화에 이은 프로트롬빈의 활성화가 최종적으로 트롬빈을 활성화하는 것으로 알려져 상기의 혈액 응고 인자의 특이적 저해 역시 중요한 혈전성 질환 치료제의 개발 타겟이 되고 있으며, 외인성 혈전 생성경로의 경우, factor II (prothrombin), V 인자, VII 인자, X인자의 활성화에 따른 혈전생성이 알려져 있다. 현재까지, 혈전성 질환의 예방과 치료에 헤파린, 쿠마린, 아스피린, 유로키네이즈 등의 다양한 항응고제, 항혈소판제, 혈전용해제 등이 사용되고 있으나, 이들은 가격이 매우 높을 뿐 아니라, 출혈성 부작용과 위장 장해 및 과민 반응 등으로 그 사용이 한정되고 있는 실정이다. In addition, the blood as a constituent of the human body has various important functions such as oxygen, nutrients, waste function and buffering action, body temperature maintenance, osmotic pressure control and ion balance maintenance, moisture maintenance, liquid control, . Normal blood circulation facilitates blood circulation by complementary regulation of the blood coagulation system and thrombolysis system in the body. Among them, the mechanism of the blood coagulation system is that the platelets adhere to the blood vessel walls and coagulate to form platelet thrombus , It is reported that the blood coagulation system is activated and fibrin thrombus is formed centering on the platelet aggregation mass. On the other hand, the production of fibrin thrombus is activated by thrombin involved in fibrin clotting through several steps of a number of blood coagulation factors to finally produce a fibrin monomer from fibrinogen. The fibrin monomers are polymerized by calcium, Cells to form a cross-linked fibrin polymer by factor XIII and produce a permanent thrombus. In addition, thrombin plays a pivotal role in thrombus formation by activating platelet, V factor, and Factor VII to promote blood coagulation. Therefore, the activity inhibitor of thrombin can be used as a prophylactic and therapeutic agent very useful for various thrombotic diseases caused by excessive blood coagulation. On the other hand, activation of prothrombin after sequential activation of factor XII, factor XI, factor XII, factor IX and factor X is finally known to activate thrombin in the endogenous thrombosis pathway, and the specific inhibition of blood clotting factor In the extrinsic thrombosis pathway, thrombogenesis is known to be caused by the activation of factors II (prothrombin), V factor, VII factor, and X factor. To date, various anticoagulants such as heparin, coumarin, aspirin, and europine have been used for the prevention and treatment of thrombotic diseases. However, these anticoagulants and thrombolytic agents are not only very expensive but also have hemorrhagic side effects, gastrointestinal disorders and hypersensitivity The use thereof is limited due to the reaction and the like.
한편, 자색고구마는 일반 고구마와 달리 강한 자색을 띈다. 이러한 자색의 주성분은 안토시아닌으로 알려져 있고, 이들 색소는 천연 식용 색소로서 널리 사용되고 있다. 안토시아닌은 약 300여종이 존재하며, 우수한 항산화 효과를 나타낸다고 알려져 있으며, 항균활성, 항고혈압 및 간 보호기능도 있는 것으로 알려져 있다.On the other hand, purple sweet potato has strong purple color unlike general sweet potato. These purple main components are known as anthocyanins, and these pigments are widely used as natural food coloring. There are about 300 kinds of anthocyanins, which are known to exhibit excellent antioxidative effects, and are known to have antimicrobial activity, antihypertensive and liver protective functions.
자색고구마와 관련된 연구는 자색고구마의 재배, 추출물 제조, 가공품 개발 및 효능 연구 등 다양하게 진행되어 왔다. 특히, 자색고구마 추출물 및 분말을 조제하고 이를 부재료로 이용한 가공식품 개발은 지속적으로 진행된 바, 자색고구마 첨가 증편(최은실 외, 2017, Journal of the Korean Society of Food Culture 32: 323-331), 자색고구마 첨가 타르트(조만재 외, 2016, 한국식품조리과학회지 32: 677-685), 자색고구마 첨가 쨈(김예림 외, 2015, Journal of the East Asian Society of Dietary Life 25: 660-666), 자색고구마 첨가 소시지(이남례 외, 2015, 한국식품영양과학회지 44: 1317-1324), 자색고구마 첨가 청국장(이민지 외, 2014, 한국식품과학회지 46: 224-230), 자색고구마 발효 막걸리(천지은, 2013, 한국식품영양학회지 26: 29-34), 자색고구마 첨가 젤리(최은진 외, 2013, 한국식품과학회지 45: 47-52)등이 알려져 있다. 또한, 자색고구마 추출물 제조에 있어서는 안토시아닌 색소 추출에 주로 집중되어 있으며, 자색고구마 색소의 최적 추출 조건은 40℃로 알려져 있고, 추출 용매로는 1% citic acid를 포함하는 20% 에탄올 등이 적합하다고 보고하였다(이장욱, 2000. 한국식품영양과학회지, 29: 790-795; 김선재 1997. 한국식품과학회지 29: 492-496; 임종환 외, 2001. 한국식품과학회지 33: 808-811). 또한, 자색고구마 효능 평가의 경우, 추출물은 70% 에탄올 등 유기용매 추출물(공봉주 외, 2014, 대한화장품학회지, 40: 423-430)을 주로 조제하여 평가하여 왔다. 그러나, 상업화와 경제성을 위해서는 유기용매 추출보다는 열수 추출이 적합하며, 열수 추출의 경우 100℃에서 90분간 추출(이유진 외, 2015. Journal of nutrition and health 48: 1-8)이 주로 진행되고 있다. Studies related to purple sweet potatoes have been carried out variously, including cultivation of purple sweet potatoes, production of extracts, development of processed products, and efficacy studies. In particular, the development of processed foods using the purple sweet potato extract and powder as a raw material has been continuously carried out. As a result, the purple sweet potato added yeast (Choi, EunSil et al., 2017, Journal of the Korean Society of Food Culture 32: 323-331) The addition of sweet potatoes (Kim, et al., 2015, Journal of the East Asian Society of Dietary Life 25: 660-666), sago with added purple sweet potato (Korean Journal of Food and Cookery Science 32: 677-685) (Korean Journal of Food Science and Nutrition 46: 224-230), fermented sweet potato fermented makkolli (Cheon Ji Eun, 2013, Korea Food Research Institute, Nutrition Journal 26: 29-34), and purple sweet potato added jelly (Choi Eun-jin et al., 2013, The Korean Journal of Food Science and Technology 45: 47-52). The optimum extraction conditions for purple sweet potato pigment are known to be 40 ℃, and 20% ethanol containing 1% citric acid is suitable for the extraction of purple sweet potato extract. (Korean Journal of Food Science and Nutrition, 29: 790-795, 1997. Korean Journal of Food Science and Nutrition 29: 492-496; Jong Hwan Lim, 2001. Korean Journal of Food Science and Nutrition 33: 808-811). In addition, in the case of purple sweet potato efficacy evaluation, the extract was evaluated mainly by preparing organic solvent extract such as 70% ethanol (Kyeongbongju et al., 2014, Journal of the Korean Society of Cosmetics, 40: 423-430). However, for commercialization and economical efficiency, hot water extraction is more suitable than organic solvent extraction. For hot water extraction, extraction is carried out at 100 ° C. for 90 minutes (Journal of nutrition and health 48: 1-8).
한편, 자색고구마의 유용 생리활성으로는 항산화 활성(김수정 외, 2010, Agricultural research bulletin of Kyungpook National University 28: 25-29), 간 보호 효과(김현아 외, 2003, 한국식생활문화학회지, 18: 202-210), 혈압강하 효과(신지영, 2000, 원광대학교 석사논문), 항염증 및 미백효과(최재홍 외, 2011, 한국식품저장유통학회지 18: 414-422) 등이 알려져 있다. In addition, the useful physiological activities of purple sweet potatoes are antioxidant activity (Kim, Hyun-ah et al., 2003, Korean Journal of Food Culture, 18: 202- (Kim Jae Hong, 2000; Wonkwang University Master's thesis), anti-inflammatory and whitening effects (Choi, Jae Hong et al., 2011, Korean Journal of Food Science and Technology 18: 414-422).
자색고구마와 관련된 특허의 경우, 대한민국 등록특허 제10-1348965호에 [자색고구마 추출물을 유효성분으로 함유하는 조성물], 등록특허 제10-1210309호에 [자색고구마 추출물을 함유하는 간섬유증 예방 및 치료용 조성물], 등록특허 제10-0426562호에 [자색고구마 추출물을 유효 성분으로 하는 숙취 해독 및 알코올성 위궤양 개선용 식품 조성물]이 개시되어 있으며, 등록특허 제10-1136059호에 [자색고구마를 이용한 생리기능성 발효주와 그 제조방법]에 혈전용해 활성이 우수한 발효주 제조가 개시되어 있다. 또한, 공개특허 제10-2011-0131855호에 [자색고구마 추출물을 함유한 아토피용 화장품], 공개특허 제10-2016-0141234호에 [자색 고구마 추출물을 이용한 간 기능 개선용 조성물, 그를 이용한 건강 기능 식품 및 그의 제조 방법] 및 공개특허 제10-2014-0047416호에 [자색고구마 막걸리를 이용한 식초의 제조방법]이 알려져 있다. In the case of a patent relating to purple sweet potato, Korean Patent No. 10-1348965 [composition containing purple sweet potato extract as an active ingredient], and registered patent No. 10-1210309 [prevention and treatment of hepatic fibrosis containing purple sweet potato extract And a food composition for improving hangover detoxification and an alcoholic gastric ulcer using the purple sweet potato extract as an active ingredient in JP-A-10-0426562, and Japanese Patent Application No. 10-1136059 Functional fermented beverage and its production method], a fermented beverage having excellent thrombolytic activity has been disclosed. In addition, in Patent Publication 10-2011-0131855 [cosmetic for atopic use containing Purple Sweet Potato Extract] and Published Japanese Patent Application No. 10-2016-0141234 [composition for improving liver function using Purple Sweet Potato Extract, And a method for producing vinegar using purple sweet potato makgeolli is disclosed in JP-A-10-2014-0047416.
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 안출된 것으로서, 본 발명에서 해결하고자 하는 과제는, 수세 정선된 자색고구마를 세절하고 이를 50~70℃의 저온에서 추출 및 냉각하고, 이를 농축하여 자색고구마 농축액을 조제하고, 이에 정제수를 가하여 최종 25~35브릭스로 조절하여 제조되는 자색고구마 조성물의 제조 방법과 상기 제조 방법에 따라 제조되는 저온추출 자색고구마 조성물 및 상기 저온추출 자색고구마 조성물을 포함하는 우수한 관능성과 항산화 활성 및 항혈전 활성을 갖는 식품 및 의약 조성물과 건강 기능 식품을 제공하고자 하는 것이다. SUMMARY OF THE INVENTION The present invention has been made in order to solve the problems of the prior art as described above, and it is an object of the present invention to provide a method for producing a sweet potato by filtering and purifying the purple sweet potato washed and cooled at a low temperature of 50 to 70 캜, To prepare a purple sweet potato concentrate, which is prepared by adding purified water to the final purple sweet potato concentrate and adjusting the final purifying water to 25-35 Bricks, and a low-temperature extracted purple sweet potato composition and a low-temperature extracted purple sweet potato composition prepared according to the above- And to provide a food, a pharmaceutical composition and a health functional food having antioxidant activity and antithrombotic activity.
상기와 같은 과제를 해결하기 위하여, 본 발명은 자색고구마를 50~70℃의 열수로 추출한 후, 냉각 및 농축하여 자색고구마 농축액을 조제하고, 상기 자색고구마 농축액에 정제수를 가하여 최종 25~35브릭스로 조절하는 항산화 활성 및 항혈전 활성을 갖는 자색고구마 조성물의 제조 방법을 제공한다.In order to solve the above problems, the present invention relates to a method for preparing a purple sweet potato concentrate by extracting purple sweet potato with hot water at 50 to 70 캜, cooling and concentrating the purple sweet potato concentrate, adding purified water to the purple sweet potato concentrate, The present invention provides a method for preparing a purple sweet potato composition having antioxidant activity and antithrombotic activity.
또한, 본 발명은 상기 기재된 방법으로 제조되는 항산화 활성 및 항혈전 활성을 갖는 자색고구마 조성물을 제공한다.The present invention also provides a purple sweet potato composition having antioxidative activity and antithrombotic activity, which is prepared by the above-described method.
상기 자색고구마 조성물은 식품 조성물 또는 의약 조성물인 것이 바람직하다.The purple sweet potato composition is preferably a food composition or a pharmaceutical composition.
또한, 본 발명은 상기 본 발명의 자색고구마 조성물을 포함하는 항산화용 건강 기능 식품을 제공한다.The present invention also provides a health functional food for antioxidation comprising the purple sweet potato composition of the present invention.
또한, 본 발명은 상기 본 발명의 자색고구마 조성물을 포함하는 혈전증의 예방 또는 개선용 건강 기능 식품을 제공한다.The present invention also provides a health functional food for preventing or ameliorating thrombosis comprising the purple sweet potato composition of the present invention.
본 발명의 저온추출법에 의한 자색고구마 조성물은, 본 명세서의 실시예를 통해 증명된 바와 같이, 조성물의 당도가 30브릭스로 조정되어 관능성이 우수하면서, 항산화 활성이 강력하며, 혈전 생성 관련 효소 저해 및 혈액 응고 인자의 저해에 의한 항응고 활성 및 혈소판 응집저해 활성을 나타냄과 동시에, 인간 적혈구에 대한 용혈 활성을 전혀 나타내지 않고, 열 안정성이 우수하고, pH 2의 산성 조건 및 혈장 내에서도 혈전 생성 관련 효소 및 혈액 응고인자 저해 효과의 손실이 나타나지 않으므로, 산화적 스트레스에 의한 각종 성인병과 혈행 개선을 통해 허혈성 뇌졸중 및 출혈성 뇌졸중과 같은 혈전증의 예방 및 치료용으로 사용할 수 있을 것으로 기대되며, 상기 유효성분은 추출액, 분말, 환, 정 등의 다양한 형태로 가공되어 상시 복용이 가능한 형태로 조제할 수 있는 뛰어난 효과가 있으므로 식품 산업 및 제약 산업상 매우 유용한 발명인 것이다. The purple sweet potato composition by the low temperature extraction method of the present invention has excellent antioxidant activity and is excellent in thrombogenic activity and inhibition of thrombogenesis as demonstrated by the examples of the present invention that the sugar content of the composition is adjusted to 30 bricks, And exhibits anticoagulant activity and platelet aggregation inhibitory activity by the inhibition of blood coagulation factors, exhibits no hemolytic activity on human erythrocytes, exhibits excellent thermal stability, exhibits an acidic condition of
도 1은 본 발명의 실시예에서 사용된 저온추출 자색고구마 조성물의 인간 혈소판 응집저해 활성을 나타낸 것이다. 여기에서, 1: 용매 대조구(DMSO), 2: 아스피린(0.25mg/ml), 3: 아스피린(0.125mg/ml), 4: 용매 대조구(물), 5: 저온추출 자색고구마 조성물의 1/10 희석액(3브릭스), 6: 저온추출 자색고구마 조성물(30브릭스)를 각각 나타낸다.FIG. 1 shows human platelet aggregation inhibitory activity of the low-temperature extracted purple sweet potato composition used in the examples of the present invention. Herein, 1/10 of the low-temperature extracted purple sweet potato composition (1: solvent control (DMSO), 2: aspirin (0.25 mg / ml), 3: aspirin (0.125 mg / Diluted solution (3 bricks), and 6: low temperature extracted purple sweet potato composition (30 bricks).
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자들은 자색고구마 저온 열수 추출물을 대상으로 항산화 및 항혈전 효능을 검정하기 위하여, 일정 방법으로 조제한 자색고구마 조성물의 관능성, 항산화 및 항혈전 활성을 평가하여, 자색고구마 조성물이 관능성과 항산화 및 항혈전 활성이 우수함을 확인하였다. 상기 조성물은 인간 적혈구에 대해 용혈 활성은 전혀 나타내지 않으면서도, 열 안정성과 산 안정성이 우수한 특징을 가짐을 확인함으로써 상기 조성물을 항산화 및 혈전증의 예방 또는 치료/개선용 약학 조성물 및 건강 기능 식품으로 활용하고자 하였다. The inventors of the present invention evaluated the functional, antioxidant and antithrombotic activity of a purple sweet potato composition prepared by a certain method in order to test antioxidative and antithrombogenic effects against the hot water extract of purple sweet potato at low temperature, And antithrombotic activity. The above composition has excellent heat stability and acid stability, while showing no hemolytic activity against human erythrocytes. Thus, the composition is used as a pharmaceutical composition for the prevention or treatment / improvement of antioxidant and thrombosis and as a health functional food Respectively.
구체적으로, 본 발명자들은 민간에서 다양한 생리 활성이 있다고 알려진 자색고구마를 이용하여 항산화 및 혈전증의 예방 또는 치료/개선용 약학 조성물 및 건강 기능 식품을 개발하기 위하여, 수세 정선된 자색고구마를 세절하고 이를 50~70℃에서 저온 추출한 후, 이를 냉각 및 농축하여 자색고구마 농축액을 조제하고, 이에 정제수를 가하여 최종 25~35브릭스로 조절한 조성물을 제조하였다. 제조된 조성물을 대상으로 항산화 활성 및 항혈전 활성을 평가하여, 상기 조성물이 우수한 관능성, 항산화 활성, 항혈전 활성이 나타냄을 확인하였다. 또한, 상기 조성물은 1mg/ml 농도에서도 인간 적혈구에 대한 용혈활성을 전혀 나타내지 않아 급성독성을 유발하지 않음을 확인하였다. Specifically, the present inventors used purple sweet potatoes known to have various physiological activities in the private sector to purify the purple sweet potatoes soaked in water to develop a pharmaceutical composition and a health functional food for prevention or treatment / improvement of antioxidant and thrombosis, The mixture was cooled and concentrated to prepare a purple sweet potato concentrate. Purified water was added thereto to prepare a final composition adjusted to 25-35 Bricks. Antioxidant activity and antithrombotic activity of the thus-prepared composition were evaluated, and it was confirmed that the composition exhibited excellent functionalities, antioxidative activity and antithrombotic activity. In addition, the composition showed no hemolytic activity against human erythrocytes even at a concentration of 1 mg / ml and thus did not cause acute toxicity.
따라서, 본 발명은 자색고구마를 50~70℃의 열수로 추출한 후, 냉각 및 농축하여 자색고구마 농축액을 조제하고, 상기 자색고구마 농축액에 정제수를 가하여 최종 25~35브릭스로 조절하는 항산화 활성 및 항혈전 활성을 갖는 자색고구마 조성물의 제조 방법을 제공한다.Accordingly, the present invention relates to a method for preparing a purple sweet potato concentrate by extracting purple sweet potato with hot water at 50 to 70 캜, cooling and concentrating the concentrate to prepare purple sweet potato concentrate, adding purified water to the purple sweet potato concentrate to control the final 25-35 brix, The present invention provides a method for producing a purple sweet potato composition having an activity.
또한, 본 발명은 상기 기재된 방법으로 제조되는 항산화 활성 및 항혈전 활성을 갖는 자색고구마 조성물을 제공한다.The present invention also provides a purple sweet potato composition having antioxidative activity and antithrombotic activity, which is prepared by the above-described method.
상기 자색고구마 조성물은 식품 조성물 또는 의약 조성물인 것이 바람직하다.The purple sweet potato composition is preferably a food composition or a pharmaceutical composition.
또한, 본 발명은 상기 본 발명의 자색고구마 조성물을 포함하는 항산화용 건강 기능 식품을 제공한다.The present invention also provides a health functional food for antioxidation comprising the purple sweet potato composition of the present invention.
또한, 본 발명은 상기 본 발명의 자색고구마 조성물을 포함하는 혈전증의 예방 또는 개선용 건강 기능 식품을 제공한다.The present invention also provides a health functional food for preventing or ameliorating thrombosis comprising the purple sweet potato composition of the present invention.
이하에서는, 본 발명의 자색고구마 저온 열수 추출 농축액을 포함하는 자색고구마 조성물의 제조 방법 및 효능 실험 등을 보다 구체적으로 설명한다.Hereinafter, a method for producing a purple sweet potato composition containing the purple hot-water hot-water extract concentrate of purple sweet potato of the present invention and an efficacy experiment will be described in more detail.
본 발명의 발명자들은, 바람직한 구체예로서, 정선, 세척된 자색고구마를 세절하는 단계: 세절된 자색고구마를 60℃에서 12시간 동안 저온 추출한 후, 이를 15℃로 냉각하고, 이를 감압농축하여 자색고구마 농축액을 조제하는 단계; 농축액에 정제수를 가하여 최종 30브릭스로 조절한 조성물을 조제하는 단계; 상기 조성물의 관능성, 항산화 활성 및 항혈전 활성 평가 및 조성물의 안정성 평가 단계의 실험들을 수행하였다.The inventors of the present invention, as a preferred embodiment, have found that a sweet potato having a purple color and a washed purple color is extracted at a low temperature for 12 hours at 60 DEG C, cooled to 15 DEG C, Preparing a sweet potato concentrate; Adding purified water to the concentrate to prepare a composition adjusted to 30 bricks final; Experiments were conducted on the functional, antioxidative and antithrombotic activities of the composition and the evaluation of the stability of the composition.
본 발명에 의하면, 본 발명의 자색고구마 농축액을 포함하는 30브릭스 당도의 자색고구마 조성물은 1/10로 희석된 상태에서도 인간 혈소판 응집도 88%를 나타내었으며, 희석전 조성물은 64.5%의 응집도를 나타내어 매우 우수한 혈소판 응집저해 활성을 가짐을 보여주었다. 또한, 본 발명의 자색고구마 농축액을 포함하는 30브릭스 당도의 조성물은 1/10로 희석된 상태에서도 70%의 DPPH 음이온 소거능, 88.6%의 ABTS 양이온 소거능, 0.922(700nm 흡광도)의 환원력을 나타내어 매우 강력한 항산화 활성을 가짐을 보여주었다. 강력한 항산화 활성은 노화 억제, 항염증 등의 산화적 스트레스 완화에 기여함은 물론 혈전 생성 억제에도 기여하는 것으로 알려져 있다. 최근 혈전 생성에는 염증반응과 산화적 스트레스가 직접 관련되어 있음이 보고되어 있으며(Martinez M 등, 2013. Free Radio. Biol. Med. 65: 411-418), 산화적 스트레스는 fibrinogen의 구조적 변화를 유발하고, oxidized-fibrinogen, cysteine-modified fibrinogen의 증가는 다양한 심혈관계 질환과 밀접히 연관되어 있음이 알려져 있다(Bijak M 등, 2011. Fitoterapia 82: 811-817; Chen H 등, 2013. Thrombosis Res. 131: 173-177). 또한 본 발명의 조성물 내의 활성 성분은 혈장 내의 다양한 분해효소에 분해되지 않으며, 100℃의 열처리와 pH 2의 인체 위 내의 pH에서도 활성을 유지한다.According to the present invention, the purple sweet potato composition having a purple sweet potato concentration of 30 bricks containing the concentrate of the present invention showed a human platelet aggregation degree of 88% even in a dilution of 1/10, and the composition before dilution showed an aggregation degree of 64.5% And showed excellent platelet aggregation inhibitory activity. In addition, the composition of the present invention containing a purple sweet potato concentrate at 30 bricks exhibited a DPPH anion scavenging ability of 70%, an ABTS cation scavenging ability of 88.6%, and a reducing power of 0.922 (absorbance of 700 nm) Antioxidant activity. Strong antioxidant activity is known to contribute not only to oxidative stress such as anti - aging, anti - inflammation but also to inhibit thrombogenesis. Recently, it has been reported that inflammatory response and oxidative stress are directly related to thrombus formation (Martinez M et al., 2013. Free Radio. Biol. Med. 65: 411-418), oxidative stress induces structural changes of fibrinogen (Bijak M, et al., 2011. Fitoterapia 82: 811-817; Chen H et al., 2013. Thrombosis Res. 131: The role of thrombosis in the development of cardiovascular disease, 173-177). In addition, the active ingredient in the composition of the present invention is not decomposed into various degrading enzymes in the plasma, and maintains its activity even at a temperature of 100 ° C and a pH of 2 on the human body.
본 발명의 저온추출 자색고구마 조성물은 우수한 관능성뿐만 아니라, 항산화 활성 및 항혈전 활성을 가지므로, 본 발명의 저온 추출 자색고구마 조성물은 상기 활성을 갖는 식품 및 의약 조성물로서 적용될 수 있다. 또한, 본 발명의 자색고구마 조성물은 항산화용 건강 기능 식품 및 혈전증의 예방 또는 개선용 건강 기능 식품으로서도 적용 가능하다. Since the low-temperature extracted purple sweet potato composition of the present invention has not only excellent functionality but also antioxidant activity and antithrombotic activity, the low-temperature extracted purple sweet potato composition of the present invention can be applied as a food and a pharmaceutical composition having the above-mentioned activity. The purple sweet potato composition of the present invention is also applicable as a health functional food for antioxidation and a health functional food for preventing or improving thrombosis.
항산화 활성과 관련된 질환들은, 예를 들어, 노화 방지, 염증 개선, 뇌혈관 질환의 개선, 심혈관 질환의 개선 등을 들 수 있다.The diseases associated with antioxidant activity include, for example, prevention of aging, improvement of inflammation, improvement of cerebrovascular disease, improvement of cardiovascular disease, and the like.
혈전증과 관련된 다양한 질환들은, 예를 들어, 동맥 혈전증으로서, 급성 심근 경색증, 가슴 통증, 호흡 곤란, 의식 소실, 허혈성 뇌졸중, 출혈성 뇌졸중, 두통, 운동 이상, 감각 이상, 성격 변화, 시력 저하, 간질 발작, 폐 혈전증, 심부정맥 혈전증, 하지 부종, 통증 및 급성 말초 동맥 폐쇄증 등을 들 수 있고, 정맥 혈전증으로서, 심부정맥 혈전증, 간문맥 혈전증, 급성 신장정맥 폐쇄증, 뇌 정맥동 혈전증 및 중심 망막정맥 폐쇄 등을 들 수 있다.Various diseases associated with thrombosis include, for example, arterial thrombosis such as acute myocardial infarction, chest pain, dyspnea, loss of consciousness, ischemic stroke, hemorrhagic stroke, headache, dysesthesia, sensory abnormality, personality change, , Venous thrombosis, portal vein thrombosis, acute renal vein thrombosis, cerebral sinus thrombosis, and central retinal vein occlusion as pulmonary thrombosis, deep vein thrombosis, deep vein thrombosis, lower limb swelling, pain and acute peripheral artery occlusion. .
본 발명의 유효 성분을 포함하는 약학 조성물은 각각의 사용 목적에 맞게 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁제, 에멀젼, 시럽, 에어로졸 등의 경구 제형, 멸균 주사용액의 주사제 등 다양한 형태로 제형화하여 사용할 수 있으며, 경구 투여하거나 정맥 내, 복강 내, 피하, 직장, 국소 투여 등을 포함한 다양한 경로를 통해 투여될 수 있다.The pharmaceutical composition containing the active ingredient of the present invention may be formulated into tablets, capsules, suspensions, emulsions, oral formulations such as syrups and aerosols, injections of sterilized injection solutions, etc. May be formulated into various forms and may be administered by various routes including oral administration or intravenous, intraperitoneal, subcutaneous, rectal, topical administration and the like.
이러한 약학 조성물에는 추가적으로 담체, 부형제 또는 희석제 등이 더 포함될 수 있으며, 포함될 수 있는 적합한 담체, 부형제 또는 희석제의 예로는 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리쓰리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 비정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다. 또한, 본 발명의 약학 조성물은 충전제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 더 포함할 수도 있다.Such pharmaceutical compositions may further comprise carriers, excipients or diluents, and examples of suitable carriers, excipients or diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch , Acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil . In addition, the pharmaceutical composition of the present invention may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, an antiseptic, and the like.
바람직한 구체예로서, 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 약학 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로오스, 락토오스, 젤라틴 등을 혼합하여 제형화한다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 등과 같은 윤활제가 사용될 수도 있다.In a preferred embodiment, the solid dosage forms for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose , Lactose, gelatin and the like are mixed and formulated. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used.
바람직한 구체예로서, 경구용 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 예시될 수 있으며, 흔히 사용되는 단순 희석제인 물, 액체 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Examples of the oral liquid preparation include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, Perfumes, preservatives, and the like.
바람직한 구체예로서, 비경구 투여를 위한 제제에는 멸균된 수용액제, 비수성용제, 현탁제, 유제, 동결건조제, 좌제 등을 예시할 수 있다. 비수성용제, 현탁제에는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 포함될 수 있다. 주사제에는 용해제, 등장화제, 현탁화제, 유화제, 안정화제, 방부제 등과 같은 종래의 첨가제가 포함될 수 있다.As a preferable specific example, the preparation for parenteral administration includes sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-drying agents, suppositories, and the like. Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Injectables may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, preservatives, and the like.
본 발명의 유효 성분은 약제학적으로 유효한 양으로 투여한다. 본 발명에서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The active ingredient of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, The sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
바람직한 구체예로서, 본 발명의 약학 조성물에서 유효성분의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 ㎏ 당 1 내지 5,000mg, 바람직하게는 100 내지 3,000mg을 매일 또는 격일 투여하거나 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나, 투여 경로, 질병의 중증도, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.As a preferable example, the effective amount of the active ingredient in the pharmaceutical composition of the present invention may vary depending on the age, sex, and body weight of the patient, and is generally 1 to 5,000 mg, preferably 100 to 3,000 mg per kg of body weight per day, It can be administered every other day or one to three times a day. However, the dosage may not be limited in any way because it may be increased or decreased depending on route of administration, severity of disease, sex, weight, age, and the like.
본 발명의 약학 조성물은 다양한 경로를 통하여 대상에 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관 내(intracerebroventricular) 주사에 의해 투여될 수 있다.The pharmaceutical composition of the present invention can be administered to a subject through various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
본 발명에서 "투여"는 임의의 적절한 방법으로 환자에게 소정의 물질을 제공하는 것을 의미하며, 본 발명의 약학 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 일반적인 모든 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명의 조성물은 유효성분을 표적 세포로 전달할 수 있는 임의의 장치를 이용해 투여될 수도 있다.In the present invention, "administration" means providing a predetermined substance to the patient in any suitable manner, and the administration route of the pharmaceutical composition of the present invention is oral or parenteral ≪ / RTI > The composition of the present invention may also be administered using any device capable of delivering an effective ingredient to a target cell.
본 발명에서 "대상"은, 특별히 한정되는 것은 아니지만, 예를 들어, 인간, 원숭이, 소, 말, 양, 돼지, 닭, 칠면조, 메추라기, 고양이, 개, 마우스, 쥐, 토끼 또는 기니아 피그를 포함하고, 바람직하게는 포유류, 보다 바람직하게는 인간을 의미한다.In the present invention, the term "object" includes, but is not limited to, human, monkey, cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig , Preferably a mammal, more preferably a human.
또한, 본 발명의 식품 조성물 및 건강 기능 식품은 항산화 및 항혈전의 예방 또는 개선에 효과적인 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 유효성분을 포함하는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.In addition, the food composition and the health functional food of the present invention can be variously used for foods and beverages effective for preventing or improving antioxidant and antithrombotic activity. Examples of foods containing the active ingredient of the present invention include various foods, beverages, gums, tea, vitamin complex, health supplement foods and the like, and they can be used in the form of powder, granule, tablet, capsule or beverage .
본 발명의 유효성분은 일반적으로 전체 식품 중량의 0.01 내지 50중량%로 가할 수 있으며, 건강음료 조성물은 100ml를 기준으로 0.02 내지 50g, 바람직하게는 0.3 내지 10g의 비율로 가할 수 있다.The active ingredient of the present invention may generally be added in an amount of 0.01 to 50% by weight of the total food, and the health beverage composition may be added in a proportion of 0.02 to 50 g, preferably 0.3 to 10 g, based on 100 ml.
본 발명의 건강 기능 식품은 지시된 비율로 필수 성분으로서 상기 화합물을 함유하는 것 외에 식품학적으로 허용 가능한 식품보조 첨가제, 예컨대, 천연 탄수화물 및 다양한 향미제 등을 추가 성분으로서 함유할 수 있다. The health functional food of the present invention may contain, as an additional ingredient, a food-acceptable food-aid additive such as natural carbohydrates and various flavors, in addition to containing the above-mentioned compound as an essential ingredient in the indicated ratio.
상기 천연 탄수화물의 예로는 포도당, 과당 등의 단당류, 말토오스, 수크로오스 등의 이당류 및 덱스트린, 시클로덱스트린 등의 다당류와 같은 통상적인 당 및 자일리톨, 소르비톨, 에리쓰리톨 등의 당알코올이 있다. Examples of the natural carbohydrate include sugar sugars such as glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol.
상기 향미제로는 타우마틴; 레바우디오시드 A 또는 글리시르히진과 같은 스테비아 등의 천연 향미제 및 사카린, 아스파르탐 등의 합성 향미제를 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강 기능 식품 100ml당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g을 사용한다. 상기 외에 본 발명의 건강 기능 식품은 여러 가지 영양제, 비타민, 광물, 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강 기능 식품은 천연 과일 주스 및 과일 주스 음료 및 야채 음료 등의 제조를 위한 과육을 함유할 수도 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 본 발명의 유효성분 100중량부 당 0.01 내지 약 20중량부의 범위에서 선택되는 것이 일반적이다.Examples of the flavoring agent include tau martin; Natural flavoring agents such as stevia such as rebaudioside A or glycyrrhizin, and synthetic flavoring agents such as saccharin and aspartame. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the health functional food of the present invention. In addition to the above, the health functional food of the present invention may contain various kinds of nutrients, vitamins, minerals, flavors such as synthetic flavors and natural flavors, colorants and heavy stabilizers, pectic acid and its salts, alginic acid and its salts, Thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the health functional food of the present invention may contain flesh for producing natural fruit juice, fruit juice drink, vegetable drink and the like. These components may be used independently or in combination. The ratio of such additives is generally selected in the range of 0.01 to about 20 parts by weight per 100 parts by weight of the active ingredient of the present invention.
이하, 본 발명의 구체적인 방법을 실시예를 통하여 보다 상세하게 설명한다. 하기 실시예는 본 발명의 바람직한 하나의 구체예일뿐이며, 본 발명의 권리범위가 하기 실시예의 범위로 한정되는 것은 아니다.Hereinafter, the specific method of the present invention will be described in more detail by way of examples. The following examples are only a preferred embodiment of the present invention, and the scope of the present invention is not limited to the scope of the following examples.
[실시예][Example]
실시예Example 1: 저온 추출 1: low temperature extraction 자색고구마Purple sweet potato 조성물의 제조 Preparation of composition
경북 안동산 자색고구마를 구입한 후 이물질을 제거하고, 선별한 후, 세절하고 이를 60℃에서 12시간 저온 추출한 후, 15℃로 냉각하고, 이를 감압농축하여 자색고구마 농축액을 조제였다. 조제된 농축액에 정제수를 가하여 최종 30brix로 조절한 조성물을 제조하였다. 제조된 조성물은 관능성이 매우 우수하였으며, 35brix를 초과하는 경우에는 단맛과 고구마향이 너무 강하여 선호도가 낮았으며, 25brix 미만의 경우 역시 선호도가 낮게 나타났다. 또한, 20brix 이하의 경우 30brix 조성물보다 미생물 오염에 취약한 것으로 나타났다. 또한, 자색고구마 추출에 있어, 50℃ 미만에서는 추출효율이 감소하며, 70℃를 초과하는 경우에는 자색 색소의 파괴 및 열 손실이 나타나 최종적으로 60℃ 추출이 가장 바람직하며, 추출시간은 12시간이 가장 최적임을 확인하였다. After purchasing purple sweet potatoes from Andong Mountain in Gyeongbuk Province, the foreign substances were removed, and they were sieved. After they were extracted at 60 ° C for 12 hours at low temperature, they were cooled to 15 ° C and concentrated under reduced pressure to prepare a purple sweet potato concentrate. Purified water was added to the prepared concentrated solution to prepare a composition adjusted to a final 30brix. The sensory properties of the prepared composition were very good. When it exceeded 35brix, the sweetness and sweet potato flavor were too strong and the preference was low. Also, the preference was lower than 25brix. In case of 20brix or less, it was found to be more susceptible to microbial contamination than 30brix composition. In the case of purple sweet potato extract, the extraction efficiency decreases at a temperature lower than 50 ° C. When the temperature is higher than 70 ° C, the purple dye breakage and heat loss are observed. Finally, 60 ° C extraction is the most preferable. And it was confirmed that it is the most optimal.
실시예Example 2: 저온 추출 2: low temperature extraction 자색고구마Purple sweet potato 조성물의 성분 분석 Composition analysis of composition
싱시예 1로부터 제조된 자색고구마 조성물의 성분 분석으로 총 폴리페놀, 총 플라보노이드, 총 당 및 환원당 함량을 측정하였다. 총 폴리페놀 함량은 추출 검액 400μl에 50μl의 Folin-ciocalteau, 100μl의 Na2CO3 포화용액을 넣고 실온에서 1시간 방치한 후 725nm에서 흡광도를 측정하였다. 표준시약으로는 tannic acid를 사용하였다. 총 플라보노이드 함량은 각각의 시료를 18시간 메탄올 교반 추출하고, 여과한 추출 검액 400μl에 90% diethylene glycol 4ml를 첨가하고 다시 1N NaOH 40μl를 넣고 37℃에서 1시간 반응 후 420nm에서 흡광도를 측정하였다. 표준시약으로는 rutin을 사용하였다. 환원당은 DNS법으로, 총 당은 phenol-sulfuric acid법을 이용하여 정량하였다. 시료 대조구로는 유사한 시판 농축 스틱제품 2종을 사용하였다. Total polyphenols, total flavonoids, total sugars and reducing sugar content were determined by component analysis of the purple sweet potato compositions prepared from Xixi Example 1. Total polyphenol content was determined by adding 50 μl of Folin-ciocalteau and 100 μl of saturated Na 2 CO 3 solution to 400 μl of the extract solution, leaving it at room temperature for 1 hour and measuring the absorbance at 725 nm. Tannic acid was used as a standard reagent. The total flavonoid content of each sample was measured by stirring for 18 hours in methanol. To the 400 μl of the filtered extract, 4 ml of 90% diethylene glycol was added and 40 μl of 1N NaOH was added. The reaction was carried out at 37 ° C. for 1 hour and then absorbance was measured at 420 nm. As a standard reagent, rutin was used. Reducing sugar was quantified by DNS method and total sugar was quantified by phenol-sulfuric acid method. Two commercial thickened sticks were used as the sample control.
그 결과, 표 1에 나타낸 바와 같이, 본 발명의 조성물은 총 폴리페놀 함량은 3.32mg/g, 총 플라보노이드 함량은 0.35mg/g으로 낮게 나타났으며, 총당은 240mg/g으로 매우 높게 나타났다. 환원당 함량은 104mg/g을 나타내어 전체 총당의 43%에 해당하였다. 그러나, 기존 시판 제품과 비교시 본 발명의 조성물은 높은 플라보노이드 함량이 특징적이었다. As a result, as shown in Table 1, the composition of the present invention had a total polyphenol content of 3.32 mg / g and a total flavonoid content of 0.35 mg / g and a total sugar content of 240 mg / g. The reducing sugar content was 104 mg / g, corresponding to 43% of the total sugar content. However, when compared with conventional commercial products, the compositions of the present invention were characteristic of high flavonoid contents.
실시예Example 3: 3: 자색고구마Purple sweet potato 조성물의 항산화 활성 Antioxidative activity of the composition
실시예 1에서 조제된 본 발명의 조성물의 1/10 희석액을 대상으로 항산화 활성을 평가하였으며, DPPH 음이온 소거능, ABTS 양이온 소거능 및 환원력을 평가하였다. 각각의 분석방법은 기존 보고와 동일하게 진행하였으며(김미선, 손호용, 2016. 한국생명과학회지 26: 1400-1408), 그 결과는 표 2에 나타내었다. The antioxidative activity of the 1/10 dilution of the composition of the present invention prepared in Example 1 was evaluated, and the DPPH anion scavenging ability, ABTS cation scavenging ability and reducing power were evaluated. Each analysis method was carried out in the same way as the previous reports (Kim, Sun-Ho, 2016. Korea Biology Journal 26: 1400-1408), and the results are shown in Table 2.
표 2에 나타낸 바와 같이, 본 발명의 조성물은 기존 시판 제품보다 매우 강력한 항산화 활성을 나타내었으며, 특히, 유사한 총 폴리페놀 함량을 가진 시판 제품 2에 비해 1.67배의 DPPH 소거능 및 1.44배의 환원력을 나타내었다. 이러한 결과는 자색고구마의 저온 추출물이 우수한 항산화 활성물질을 포함하고 있음을 의미하며, 이러한 항산화 활성은 혈관내 혈전 생성 억제에 긍정적으로 기여하리라 판단된다.As shown in Table 2, the composition of the present invention exhibited a stronger antioxidative activity than conventional commercial products, and exhibited a DPPH scavenging power of 1.67 times and a reduction power of 1.44 times that of the
실시예Example 4: 4: 자색고구마Purple sweet potato 조성물의 혈액응고 저해활성 평가 Evaluation of blood coagulation inhibitory activity of the composition
실시예 1에서 조제된 본 발명의 조성물 1/10 희석액을 대상으로 혈액응고 저해활성(혈전생성 억제활성)을 평가하였으며, 기존에 보고된 방법(Sohn et al., 2004. Kor. J. Pharmacogn 35. 521; Kwon et al., 2004. J. Life Science, 14. 509-513; 류 등 2010. J. Life Science, 20. 922-928)과 동일하게, 트롬빈 타임, 프로트롬빈 타임, 에이피티 타임을 측정하여 평가하였다. 혈장은 시판 control plasma(MD Pacific Technology Co., Ltd, Huayuan Industrial Area, China)를 사용하였으며 트롬빈 타임, 프로트롬빈 타임과 에이피티 측정법은 다음과 같은 과정으로 수행되었다.The blood coagulation inhibitory activity (thrombogenesis inhibitory activity) of the 1/10 dilution of the composition of the present invention prepared in Example 1 was evaluated and compared with the previously reported method (Sohn et al., 2004. Kor J. Pharmacogn 35 , Prostrombin Time, and Apitime Time, as in Kwon et al., 2004. J. Life Science, 14. 509-513; And evaluated. Plasma was obtained from a commercial control plasma (MD Pacific Technology Co., Ltd., Huayuan Industrial Area, China), and the thrombin time, prothrombin time and api assay were performed as follows.
트롬빈 타임(Thrombin Time)Thrombin Time
37℃에서 0.5U 트롬빈(Sigma Co., USA) 50μl와 20 mM CaCl2 50μl, 다양한 농도의 시료 추출액 10μl를 Amelung coagulometer KC-1A(Japan)의 튜브에 혼합하여 2분간 반응시킨 후, 혈장 100μl를 첨가한 후 혈장이 응고될 때까지의 시간을 측정하였다. 대조로는 아스피린(Sigma Co., USA)을 사용하였으며, 용매 대조구로는 시료 대신 DMSO를 사용하였다. DMSO의 경우 30.5초의 응고시간을 나타내었다. 트롬빈 저해 효과는 3회 이상 반복한 실험의 평균치로 나타내었으며, 트롬빈 저해 활성은 시료 첨가시의 응고시간을 용매 대조구의 응고시간으로 나눈 값으로 나타내었다.50 μl of 0.5 U thrombin (Sigma Co., USA) and 50 μl of 20 mM CaCl 2 and 10 μl of various concentrations of the sample extract were mixed in a tube of Amelung coagulometer KC-1A (Japan) for 2 minutes at 37 ° C., After the addition, the time until the plasma coagulated was measured. As a control, aspirin (Sigma Co., USA) was used and DMSO was used as a solvent control instead of the sample. DMSO showed a solidification time of 30.5 sec. The thrombin inhibitory effect was expressed as the average value of the experiments repeated three or more times. The thrombin inhibitory activity was expressed by the value obtained by dividing the solidification time at the time of addition of the sample by the solidification time of the solvent control.
프로트롬빈 타임(Prothrombin time ( prothrombinprothrombin time) time)
표준혈장(MD Pacific Co., China) 70μl와 다양한 농도의 시료액 10μl를 Amelung coagulometer KC-1A(Japan)의 튜브에 첨가하여 37℃에서 3분간 가온 후, 130μl의 PT reagent를 첨가하고 혈장이 응고될 때까지의 시간을 3회 반복한 실험의 평균치로 나타내었다. 대조로는 아스피린(Sigma Co., USA)을 사용하였으며, 용매 대조구로는 시료 대신 DMSO를 사용하였다. DMSO의 경우 16.7초의 응고시간을 나타내었다. 프로트롬빈 저해활성은 시료 첨가시의 응고시간을 용매 대조구의 응고시간으로 나눈 값으로 나타내었다.Add 70 μl of standard plasma (MD Pacific Co., China) and 10 μl of various concentrations of sample solution to tubes of Amelung coagulometer KC-1A (Japan), heat at 37 ° C for 3 minutes, add 130 μl of PT reagent, The time from the start of the experiment to the start of the experiment was expressed as the average value of the experiments repeated three times. As a control, aspirin (Sigma Co., USA) was used and DMSO was used as a solvent control instead of the sample. DMSO showed a clotting time of 16.7 seconds. The prothrombin inhibitory activity was expressed as the value obtained by dividing the solidification time at the time of addition of the sample by the solidification time of the solvent control.
aPTTaPTT (activated Partial (activated Partial ThromboplastinThromboplastin Time) Time)
혈장 100μl와 다양한 농도의 시료 추출액 10μl를 Amelung coagulometer KC-1A(Japan)의 튜브에 첨가하여 37℃에서 3분간 가온한 후, 50μl의 aPTT reagent(Sigma, ALEXINTM )를 첨가하고 다시 37℃에서 3분간 배양하였다. 이후 50μl CaCl2(35mM)을 첨가한 후 혈장이 응고될 때까지의 시간을 측정하였다. 용매 대조구로는 시료 대신 DMSO를 사용하였으며, 이 경우 58.1초의 응고시간을 나타내었다. aPTT의 결과는 3회 반복한 실험의 평균치로 나타내었으며, 혈액응고인자 저해활성은 시료 첨가시의 aPTT를 용매 대조구의 aPTT로 나눈 값으로 나타내었다. Add 50 μl of aPTT reagent (Sigma, ALEXIN ™ ) to the tubes of Amelung coagulometer KC-1A (Japan) and incubate for 3 minutes at 37 ° C. Add 100 μl of plasma and 10 μl of various concentrations of sample extract Min. After the addition of 50 μl CaCl 2 (35 mM), the time until the plasma coagulated was measured. As the solvent control, DMSO was used instead of the sample. In this case, the solidification time was 58.1 seconds. The results of aPTT were expressed as the mean value of three repeated experiments. The activity of inhibiting blood coagulation factor was represented by aPTT divided by the aPTT of the solvent control when the sample was added.
그 결과, 표 3에 나타난 바와 같이, 본 발명의 조성물은 다른 기존 제품에 비해 우수한 트롬빈 저해 및 프로트롬빈 저해를 나타내었다. 이때, 대조구로 사용된 아스피린은 1.5mg/ml 농도에서 트롬빈 타임, 프로트롬빈 타임, 에이피티 타임을 각각 1.49배, 1.37배 및 1.33배 연장시켰다. 이러한 결과는 본 발명의 조성물이 적어도 혈액응고를 촉진하는 활성은 없음을 확인할 수 있다. As a result, as shown in Table 3, the composition of the present invention showed excellent thrombin inhibition and prothrombin inhibition as compared with other conventional products. At this time, aspirin used as a control was lengthened by 1.49, 1.37 and 1.33 times the thrombin time, prothrombin time and apathy time at the concentration of 1.5 mg / ml. These results indicate that the composition of the present invention is not at least active in promoting blood coagulation.
실시예Example 5: 5: 자색고구마Purple sweet potato 조성물의 혈소판 응집 저해 활성 평가 Evaluation of Platelet Aggregation Inhibitory Activity of the Composition
실시예 1에서 조제된 본 발명의 조성물 및 1/10 희석액을 대상으로 혈소판 응집저해 활성을 평가하여, 그 결과를 표 4 및 도 1에 나타내었다. 혈소판은 다양한 혈구세포와 함께 혈관을 순환하는 원반형의 작은 세포로서, 핵이 없는 대신 혈관손상보호 및 혈소판 응집과 관련된 다양한 물질을 고농도로 포함하는 cytoplasmic granule을 가지고 있으며, 혈관내벽의 손상이 나타나는 경우 응집인자들을 분비하고, 내피세포의 손상으로 노출된 collagen 등과 결합하여 1차 지혈 플러그(primary hemostatic plug)를 형성하여 혈전생성을 개시하는 중요한 세포이다. 따라서, 혈소판 응집저해는 혈전 생성을 방지하는 매우 중요한 활성이다. 혈소판 응집저해 활성은 다음의 방법에 준해 평가하였다. The platelet aggregation inhibitory activity of the composition of the present invention prepared in Example 1 and a 1/10 dilution was evaluated, and the results are shown in Table 4 and FIG. Platelets are cytoplasmic granules that contain various substances related to blood vessel damage protection and platelet aggregation at high concentration instead of nucleus, and circulating blood vessels together with various blood cells. It is an important cell that secretes factors and binds to collagen exposed by damage of endothelial cells to form a primary hemostatic plug to initiate thrombogenesis. Therefore, inhibition of platelet aggregation is a very important activity to prevent thrombogenesis. Platelet aggregation inhibitory activity was evaluated according to the following method.
혈소판 응집저해 활성(Platelet aggregation inhibition activity)Platelet aggregation inhibition activity (Platelet aggregation inhibition activity)
혈소판은 인간 농축혈소판을 사용하였으며, 이를 washing buffer(138mM NaCl, 2.7mM KCl, 12mM NaHCO3, 0.36mM NaH2PO4, 5.5mM Glucose, 1mM EDTA, pH 6.5)로 1회 세척하였다. 이후, suspending buffer(138mM NaCl, 2.7mM KCl, 12mM NaHCO3, 0.36mM NaH2PO4, 5.5mM Glucose, 0.49mM MgCl2, 0.25% gelatin, pH 7.4)에 재 현탁한 후, 3,000rpm에서 10분간 원심분리한 후 다시 suspending buffer에 재 현탁하였으며, 이때 혈소판 수는 4x109/ml이 되도록 조정하였다. 이후 1ml 현탁액에 2.5μl collagen을 가해 5분간 반응시키고, whole-blood aggregometer(Chrono-log, USA)를 사용하여 37℃에서 혈소판 응집을 측정하였다.Human platelets were used as platelets and washed once with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 5.5 mM Glucose, 1 mM EDTA, pH 6.5). Thereafter, the cells were resuspended in a suspending buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 5.5 mM Glucose, 0.49 mM MgCl 2 , 0.25% gelatin, pH 7.4) and incubated at 3,000 rpm for 10 minutes After centrifugation, the cells were resuspended in a suspending buffer and the platelet count was adjusted to 4 × 10 9 / ml. Then platelet aggregation was measured at 37 ° C using a whole-blood agarometer (Chrono-log, USA) after 2.5 μl of collagen was added to 1 ml of suspension and reacted for 5 minutes.
그 결과, 용매대조구인 DMSO의 경우 혈소판은 콜라겐 첨가에 의해 빠르고 강하게 응집이 나타났으며, 혈소판 응집저해제인 아스피린은 농도 의존적으로 혈소판 응집을 강력하게 저해하였다. 이때, 아스피린은 0.25mg/ml 농도에서 27.5%의 응집도, 0.125mg/ml 농도에서 58.3%의 응집도를 나타내어 임상에서 항혈전제로 사용되는 근거를 확인하였다. 한편, 본 발명의 조성물을 1/10로 희석한 시료를 사용한 경우, 혈소판 응집도는 88.7%를 나타내었으며, 조성물을 원액 그대로 시료로 사용한 경우, 64.5%의 응집도를 나타내었다. 시판 기존 제품들은 혈소판 응집에 전혀 영향을 미치지 않았다. 따라서, 본 발명의 조성물은 혈소판 응집을 농도 의존적으로 저해하여 우수한 항혈전 활성을 나타냄을 확인하였다. As a result, in the case of DMSO as a solvent control, platelets rapidly and strongly aggregated by the addition of collagen, and aspirin, which is a platelet aggregation inhibitor, strongly inhibited platelet aggregation in a concentration - dependent manner. At this time, aspirin showed a coagulation degree of 27.5% at a concentration of 0.25 mg / ml and a coagulation degree of 58.3% at a concentration of 0.125 mg / ml, thus confirming the basis for use as an antithrombotic agent in clinical practice. On the other hand, when the sample diluted 1/10 of the composition of the present invention was used, the platelet aggregation degree was 88.7%, and when the composition was used as the sample in the undiluted solution, the degree of aggregation was 64.5%. Commercially available products did not affect platelet aggregation at all. Therefore, it was confirmed that the composition of the present invention inhibits platelet aggregation in a concentration-dependent manner and exhibits excellent antithrombotic activity.
실시예Example 6: 6: 자색고구마Purple sweet potato 조성물의 인간 적혈구 용혈 활성 평가 Evaluation of human erythrocyte hemolytic activity of the composition
자색고구마는 과거부터 식용으로 사용되어 온 바, 자색고구마의 저온 열수 추출물을 포함하는 본 발명의 조성물은 특이한 독성은 없을 것으로 판단된다. 본 발명의 조성물의 잠재적 급성 독성을 평가하기 위해 인간 적혈구 용혈 활성을 평가하였으며, 그 결과는 표 5에 나타내었다. 이때, 용혈 활성은 기존의 보고(정인창, 손호용, 2014년, Korean J. Microbiol. Biotechnol. 42: 285~292)에 준해 평가하였으며, 간단하게는 PBS로 3회 수세한 인간 적혈구 100μl를 96-well microplate에 가하고 다양한 농도의 시료용액 100μl를 가한 다음 37℃에서 30분간 반응시켰으며, 이후, 반응액을 10분간 원심분리(1,500rpm)하여 상등액 100μl를 새로운 microtiter plate로 옮긴 후 용혈에 따른 헤모글로빈 유출 정도를 414nm에서 측정하였다. 시료의 용매 대조구로는 DMSO(2%)를 사용하였으며, 적혈구 용혈을 위한 실험 대조구로는 Triton X-100(1mg/ml)를 사용하였다. 용혈 활성은 다음의 수식을 이용하여 계산하였다.Purple sweet potatoes have been used for edible purposes in the past, and the composition of the present invention including a low temperature hot water extract of purple sweet potatoes is considered to have no specific toxicity. To evaluate the potential acute toxicity of the compositions of the present invention, human erythropoietic activity was evaluated and the results are shown in Table 5. At this time, hemolytic activity was evaluated according to the existing reports (Jung In-chang, Son Ho Yong, 2014, Korean J. Microbiol. Biotechnol. 42: 285 ~ 292). In brief, 100 μl of human erythrocytes, The reaction mixture was centrifuged at 1,500 rpm for 10 min. After transferring 100 μl of the supernatant to a new microtiter plate, the hemoglobin efflux Was measured at 414 nm. Triton X-100 (1 mg / ml) was used as an experimental control for erythrocyte hemolysis. DMSO (2%) was used as a solvent control of the sample. Hemolytic activity was calculated using the following formula.
(( %% ) ) HemolysisHemolysis = [( = [( AbsAbs .S-.S- AbsAbs .C)/(.C) / ( AbsAbs .T-.T- AbsAbs .C)] × 100. C)] x 100
Abs. S : 시료 첨가구의 흡광도,Abs. S: absorbance of sample added sphere,
AbsAbs . C : . C: DMSODMSO 처가구의Of furniture 흡광도, Absorbance,
AbsAbs . T : Triton X-100 . T: Triton X-100 첨가구의Additive 흡광도. Absorbance.
먼저, 대조구로 사용된 DMSO와 증류수는 적혈구 용혈 활성이 없었으며, Triton X-100은 1mg/ml 농도에서 적혈구를 100% 용혈시킴을 확인하였다. 한편, 자색고구마 저온 열수 추출물을 포함하는 본 발명의 조성물과 시판 유사제품에서는 모두 용혈활성이 나타나지 않았다. First, DMSO and distilled water used as control did not have erythrocyte hemolytic activity, and Triton X-100 showed 100% hemolysis of red blood cells at a concentration of 1 mg / ml. On the other hand, neither the composition of the present invention including the purple hot potato hot water extract of the present invention nor the commercial product showed hemolytic activity.
실시예Example 7: 7: 자색고구마Purple sweet potato 조성물의 혈장, 산 및 열 안정성 평가 Plasma, acid and thermal stability evaluation of the composition
상기 실시예 1에서 조제된 본 발명의 조성물을 대상으로 항산화 및 혈소판 응집저해 활성에 대한 혈장 안정성, 열 안정성 및 산 안정성을 확인하였다. 상기 조성물은 100℃에서 1시간 열 처리, pH 2(0.01M HCl)에서의 1시간 처리, 혈장에서 1시간 처리시에도 항산화 및 혈소판 응집저해 활성의 소실이 없이 우수한 활성을 유지하였다. The plasma stability, thermal stability and acid stability of the antioxidant and platelet aggregation inhibitory activity of the composition of the present invention prepared in Example 1 were confirmed. The composition maintained excellent activity without heat treatment at 100 ° C for 1 hour, 1 hour treatment with pH 2 (0.01M HCl), and 1 hour treatment with plasma without loss of antioxidant activity and platelet aggregation inhibitory activity.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180005766A KR102186505B1 (en) | 2018-01-16 | 2018-01-16 | The purple sweet potato composition manufactured by low temperature extraction method and the use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180005766A KR102186505B1 (en) | 2018-01-16 | 2018-01-16 | The purple sweet potato composition manufactured by low temperature extraction method and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190087233A true KR20190087233A (en) | 2019-07-24 |
| KR102186505B1 KR102186505B1 (en) | 2020-12-03 |
Family
ID=67481173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180005766A KR102186505B1 (en) | 2018-01-16 | 2018-01-16 | The purple sweet potato composition manufactured by low temperature extraction method and the use thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102186505B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021010800A1 (en) | 2019-07-18 | 2021-01-21 | 제이더블유바이오사이언스 주식회사 | Antibody specifically binding to wrs protein, and use thereof |
| JP2023043796A (en) * | 2021-09-16 | 2023-03-29 | 伊豆食文化公園株式会社 | Antibacterial composition and method for producing the same |
| JP2023043797A (en) * | 2021-09-16 | 2023-03-29 | 伊豆食文化公園株式会社 | Sweet Potato Extract, α-Glucosidase Inhibitor, and Antioxidant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030015424A (en) * | 2001-08-14 | 2003-02-25 | 충청남도 | The physiofunctional fermented liquor with purple sweet potato and the producing method of therof |
| KR101136059B1 (en) | 2008-12-02 | 2012-08-16 | 농업회사법인주식회사 무안황토명품고구마클러스터사업단 | Composition for suppressing alcoholic hangover and gastric ulcer by sweet potato fermentation fractions |
-
2018
- 2018-01-16 KR KR1020180005766A patent/KR102186505B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030015424A (en) * | 2001-08-14 | 2003-02-25 | 충청남도 | The physiofunctional fermented liquor with purple sweet potato and the producing method of therof |
| KR101136059B1 (en) | 2008-12-02 | 2012-08-16 | 농업회사법인주식회사 무안황토명품고구마클러스터사업단 | Composition for suppressing alcoholic hangover and gastric ulcer by sweet potato fermentation fractions |
Non-Patent Citations (1)
| Title |
|---|
| JOURNAL OF MEDICINAL FOOD, vol.13, no.1, pp.91-98 (2010.)* * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021010800A1 (en) | 2019-07-18 | 2021-01-21 | 제이더블유바이오사이언스 주식회사 | Antibody specifically binding to wrs protein, and use thereof |
| JP2023043796A (en) * | 2021-09-16 | 2023-03-29 | 伊豆食文化公園株式会社 | Antibacterial composition and method for producing the same |
| JP2023043797A (en) * | 2021-09-16 | 2023-03-29 | 伊豆食文化公園株式会社 | Sweet Potato Extract, α-Glucosidase Inhibitor, and Antioxidant |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102186505B1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190087233A (en) | The purple sweet potato composition manufactured by low temperature extraction method and the use thereof | |
| KR101678301B1 (en) | Pharmaceutical composition comprising the extract of ribes nigrum l. fruit as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101870952B1 (en) | Pharmaceutical composition comprising the rambutan peel extracts as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20190020889A (en) | Pharmaceutical composition comprising the extract of apios americana medikus as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20190021502A (en) | Pharmaceutical composition comprising the zingiber officinale leaf extracts as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR102075799B1 (en) | Pharmaceutical composition comprising the extract of an unripe apple as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101976202B1 (en) | Pharmaceutical composition comprising the extracts of passion fruit rind as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101916340B1 (en) | Pharmaceutical composition for prevention or treatment of thrombosis comprising the extraction of lettuce as an effective component and health functional food comprising the same | |
| KR20190085730A (en) | Pharmaceutical composition comprising the extracts from stem of actinidia arguta as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101740829B1 (en) | Pharmaceutical composition comprising the extraction of ice plant as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20190009929A (en) | Pharmaceutical composition comprising the extraction of leaf of nelumbo nucifera as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101743995B1 (en) | Pharmaceutical composition comprising the extract of sorbus commixta branch as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20200003997A (en) | Pharmaceutical composition comprising the leaf extracts of polygonium tinctorium as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101801612B1 (en) | Pharmaceutical composition comprising the extraction of kaempferia parviflora as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR102305606B1 (en) | Pharmaceutical composition comprising the extraction of hempseed as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20190066491A (en) | Pharmaceutical composition comprising the extracts from the flesh and seed of passion fruit as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101800372B1 (en) | Pharmaceutical composition comprising the extraction of unripe korean peaches as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101976203B1 (en) | Pharmaceutical composition comprising the extracts of mangosteen peduncle as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR102062136B1 (en) | Phamaceutical composition for prevention or treatment of thrombosis comprising kyung-ok-go adding the silk of zea mays and pumpkin and health functional food comprising the same | |
| KR101945733B1 (en) | Pharmaceutical composition comprising the ethanol extracts of yunnongchamssal as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101479816B1 (en) | Pharmaceutical composition comprising the extract of phellinus linteus as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR102120490B1 (en) | Pharmaceutical composition for prevention or treatment of thrombosis comprising the ethylacetate fraction of shiitake mushroom extract as an effective component and health functional food comprising the same | |
| KR101997260B1 (en) | Pharmaceutical composition comprising the extraction of nodulus of nelumbinus rhizoma as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR101990637B1 (en) | Pharmaceutical composition comprising the sprout extracts of zingiber officinale as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20200004460A (en) | Pharmaceutical composition comprising ethanol extracts of seedpod of nelumbo nucifera as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |